Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Bariatric Surgery Could Resolve Liver Disease in the Obese

By HospiMedica International staff writers
Posted on 15 Dec 2008
A recent study has found an improvement in the histopathological features of nonalcoholic fatty liver disease (NAFLD) following bariatric (weight loss) surgery.

Researchers at the University of Texas Medical Branch (Galveston, USA) conducted a meta-analysis of 15 studies involving 766 patients with paired liver biopsies. More...
Studies of jejuno-ileal bypass were excluded, as were those with fewer than 10 patients. The mean age of the participants at the time of weight loss surgery ranged from 35.6 to 49 years. The mean body mass index (BMI) at the time of surgery ranged from 43.9 to 56, and the mean BMI at follow-up liver biopsies ranged from 28.6 to 39. The percentage reduction in mean BMI values following surgery ranged from 19.11 to 41.76.

The results of the analysis showed that the pooled proportion of patients with improvement or resolution in steatosis (fat accumulation in the liver cells) was 91.6%, severe non-alcoholic steatohepatitis (NASH) resolution was 81.3%, fibrosis (which can progress to cirrhosis) resolution was 65.5%, and complete resolution of NASH was 69.5%. The researchers stressed that the confirmation of these results may require further multi-center, large scale, well designed trials, and that future studies also need to be conducted using uniform histopathological criteria for liver biopsy specimens. The study was published in the December 2008 issue of Clinical Gastroenterology and Hepatology

"Even today, the effect of weight loss after bariatric surgery on the liver, particularly NAFLD, remains unclear. There is a lack of well-defined trials exploring this relationship," said lead author Gagan Sood, M.D. "Our team assessed and quantified this effect and found encouraging news; a majority of patients experience complete resolution of NAFLD after bariatric surgery, and the risk of progression of inflammatory changes and fibrosis seems to be minimal."

NAFLD encompasses a range of conditions involving the liver that affect people who drink little or no alcohol, and ranges from hepatic steatosis to end-stage liver disease and hepatocellular carcinoma. The prevalence of NAFLD is estimated to be around 70% in obese individuals and 85-95% in patients with morbid obesity. The prevalence of NASH is as high as 18.5% in obese individuals and 33% in those who are morbidly obese. The pathophysiologic mechanisms of NAFLD have not been clearly elucidated yet, but obesity and insulin resistance are considered the main causative factors.

Related Links:
University of Texas Medical Branch



Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Digital Color Doppler Ultrasound System
MS22Plus
Head Rest
Medifa 61114_3
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.